Residency · Residency · Radiation Oncology
Combining Radiation with Immune Checkpoint Inhibitors: Safety and Sequencing
Introduction
The integration of radiation therapy with immune checkpoint inhibitors (ICIs) has become a prominent focus of clinical research across various tumor types. Radiation enhances anti-tumor immunity by inducing immunogenic cell death, releasing tumor antigens, and priming the immune system. Meanwhile, ICIs function by removing inhibitory signals that suppress T-cell activity, thereby restoring effective immune responses against cancer. This lecture explores the safety profile of combining these modalities, optimal sequencing strategies, and evidence specific to different diseases.
Rationale for Combination
Complementary Mechanisms
Radiation therapy induces immunogenic cell death, effectively creating an in situ vaccine effect by releasing tumor antigens that can stimulate the immune system. Additionally, radiation upregulates PD-L1 expression on tumor cells, which provides a target for anti-PD-1 and anti-PD-L1 therapies. Immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents, counteract the immunosuppressive environment induced by radiation. Radiation also recruits T cells into the tumor microenvironment, while ICIs help maintain their effector functions. This combination holds potential for both local synergy at the irradiated site and systemic, or abscopal, effects that impact distant tumor sites.
Immune Checkpoint Agents
The main ICIs include anti-PD-1 agents such as pembrolizumab and nivolumab, anti-PD-L1 agents like durvalumab, atezolizumab, and avelumab, and anti-CTLA-4 agents including ipilimumab and tremelimumab. Combination regimens that pair anti-PD-1 with anti-CTLA-4 antibodies have demonstrated the highest efficacy but also carry the greatest risk of toxicity.
Safety of Combined RT and ICI
General Safety Profile
Meta-analyses and prospective studies indicate that combining radiation therapy with ICIs is generally safe and well tolerated. The incidence of grade 3 or higher adverse events is comparable to that seen with ICIs alone in most studies. Furthermore, most reports do not show a significant increase in immune-related adverse events (irAEs) when radiation is administered concurrently with ICIs. Nonetheless, attention must be paid to site-specific toxicities that may arise depending on the irradiated region.
Site-Specific Toxicity Considerations
Thoracic Radiation + ICI
Pneumonitis represents the primary safety concern when thoracic radiation is combined with ICIs. In the PACIFIC trial, grade 3-4 pneumonitis occurred in 3.4% of patients receiving durvalumab compared to 2.6% in the placebo group, indicating a modest increase. Risk factors for pneumonitis include larger radiation fields, higher mean lung doses, and pre-existing lung disease. Patients should be monitored with surveillance CT scans, and ICIs should be withheld if grade 2 or higher pneumonitis develops.
Brain SRS/WBRT + ICI
Combining stereotactic radiosurgery (SRS) or whole-brain radiation therapy (WBRT) with ICIs is generally safe, with most series reporting no significant increase in radiation necrosis. Some retrospective data suggest a modest rise in symptomatic radiation necrosis when ICIs are given concurrently. However, the improved intracranial control achieved with combined therapy likely outweighs this risk. Since dexamethasone can blunt ICI efficacy, steroid exposure should be minimized whenever possible.
Abdominal/Pelvic RT + ICI
Concurrent radiation to the bowel combined with ICIs carries a risk of colitis and enteritis. It is important to distinguish radiation-induced enteritis from immune-mediated colitis, as their management differs. The highest risk of colitis occurs with concurrent use of anti-CTLA-4 agents.
Hepatic Radiation + ICI
Liver function should be closely monitored during combined hepatic radiation and ICI therapy. Hepatotoxicity from ICIs, such as autoimmune hepatitis, must be differentiated from radiation-induced liver disease (RILD). Liver stereotactic body radiation therapy (SBRT) combined with ICIs has generally been safe in reported series.
Sequencing: Timing of RT and ICI
Concurrent Administration
The strongest immunologic rationale supports concurrent administration of radiation and ICIs because radiation-induced antigen release occurs during active immune checkpoint blockade, maximizing synergistic immune activation. Most clinical trial data favor concurrent or near-concurrent approaches. For example, the PACIFIC trial administered durvalumab within 42 days of completing chemoradiation.
Neoadjuvant/Induction ICI Before RT
Administering ICIs before radiation may prime the immune system, potentially enhancing the immunogenic effects of subsequent radiation. This approach is under investigation in head and neck cancer, non-small cell lung cancer (NSCLC), and rectal cancer. However, there is a risk of tumor progression during induction ICI if the disease is aggressive.
Adjuvant/Consolidative ICI After RT
The PACIFIC trial established a model in which ICIs are initiated after completing chemoradiation. This well-studied paradigm for Stage III NSCLC allows radiation to be completed without complications related to ICIs during treatment. A potential concern is that delaying ICI initiation may permit immune suppressive recovery.
Optimal Timing Window
Preclinical data suggest that concurrent administration or initiation of ICIs within one to two weeks of radiation yields the best immune synergy. A subgroup analysis from the PACIFIC trial showed that patients starting durvalumab within 14 days of radiation completion had better outcomes. Prolonged gaps exceeding 42 days between radiation and ICI initiation should be avoided when possible.
Disease-Specific Evidence
Non-Small Cell Lung Cancer (NSCLC)
The PACIFIC trial provides definitive evidence supporting combined chemoradiation and durvalumab consolidation in Stage III NSCLC. The KEYNOTE-799 trial demonstrated acceptable safety for concurrent pembrolizumab with chemoradiation in this setting. Radiation combined with ICIs is also being increasingly studied in early-stage and oligometastatic NSCLC.
Head and Neck Squamous Cell Carcinoma
Trials such as JAVELIN Head and Neck 100, which evaluated avelumab plus chemoradiation, and KEYNOTE-412, which tested pembrolizumab plus chemoradiation, did not show progression-free survival (PFS) improvement. Currently, ICIs have not replaced cisplatin in definitive chemoradiation for head and neck squamous cell carcinoma (HNSCC). Post-radiation adjuvant ICIs like nivolumab and pembrolizumab are under investigation.
Melanoma Brain Metastases
Combining stereotactic radiosurgery with ICIs such as ipilimumab or nivolumab improves intracranial control compared to SRS alone. Anti-PD-1 agents given concurrently with SRS achieve one-year intracranial control rates of 70-80%. Retrospective data favor concurrent over sequential timing.
Cervical Cancer
The CALLA trial, which combined durvalumab with chemoradiation, did not meet its primary PFS endpoint. In contrast, the KEYNOTE-A18 trial demonstrated improved PFS with pembrolizumab plus chemoradiation, representing a practice-changing development. Integration of ICIs into standard cervical cancer chemoradiation is emerging.
Practical Considerations
Steroid Management
Corticosteroids can attenuate the efficacy of ICIs, so minimizing dexamethasone exposure is important, especially keeping doses below 10 mg prednisone equivalent when possible. Steroid-sparing antiemetics should be used, and radiation techniques may be modified to reduce edema. When steroids are necessary to manage immune-related adverse events, ICIs can be resumed after steroid taper.
Monitoring During Combined Therapy
Baseline and serial assessments of liver and thyroid function, as well as blood counts, are essential. Surveillance imaging is important for detecting pneumonitis, particularly in NSCLC and thoracic radiation cases. Clinicians should maintain a low threshold for holding ICIs in the presence of grade 2 or higher immune-related adverse events. Multidisciplinary coordination between radiation oncology and medical oncology teams is critical.
Patient Selection
Patients with autoimmune conditions are generally excluded from ICI trials due to safety concerns. Prior organ transplant is a contraindication for ICIs because of the risk of graft rejection. Eligibility decisions also consider performance status, tumor burden, and extent of systemic disease.
Ongoing and Future Directions
Future research is focusing on optimizing radiation dose and fractionation to maximize immune activation. Multi-site radiation may enhance neoantigen diversity, potentially improving immune responses. Combining radiation and ICIs with novel immunotherapy agents targeting pathways such as LAG-3, TIGIT, and STING is under investigation. Biomarker-driven patient selection and adaptive trial designs incorporating serial biomarker assessments are promising strategies to refine combined modality therapy.
Key Clinical Pearls
Combining radiation therapy with immune checkpoint inhibitors is generally safe, with grade 3 or higher toxicity rates similar to those seen with ICIs alone in most clinical settings. Pneumonitis remains the primary safety concern when thoracic radiation is combined with ICIs, necessitating vigilant monitoring with surveillance imaging. Optimal immune synergy appears to be achieved with concurrent or near-concurrent timing of radiation and ICIs, so prolonged intervals between these treatments should be avoided. Minimizing corticosteroid use is important because steroids can reduce immunotherapy efficacy. The PACIFIC trial established consolidative durvalumab after chemoradiation as the standard of care in Stage III NSCLC and serves as a model for integrating radiation and ICIs.
References
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (PACIFIC). N Engl J Med. 2017;377(20):1919-1929.
- Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467-475.
- Hwang WL, Pike LRG, Royce TJ, et al. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018;15(8):477-494.
- Loap P, Loirat D, Berger F, et al. Combination of radiation therapy with immune checkpoint blockade: safety and efficacy across tumor types. Cancer Treat Rev. 2021;95:102177.